Skip to main content
Ariana Bauer on Muck Rack

Ariana Bauer

As seen in: ONCOLOGY journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ariana

Contact Ariana, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Show and After Show Previews the 2025 ASH Annual Meeting

|
By Ram Prakash Thirugnanasambandam, Ariana Bauer, Christopher A. D’Angelo, Kristie Kahl Verified
| ONCOLOGY journal Verified
In this special edition of The Show & After-Show, co-hosts Andrew Svonavec and Kristie Kahl are shaking things up—literally. Broadcasting away from their usual studio (and relying on some "high-tech" paper scripts), the duo breaks down everything oncology providers need to know before heading to the American Society of Hematology (ASH) Annual Meeting in Orlando. ASH 2025 is set to be a landmark event for blood cancer research.
Open in Who Shared Issue with article?

Delving Into the Current State of Clinical Practice in SCLC

|
By Ram Prakash Thirugnanasambandam, Ariana Bauer, Christopher A. D’Angelo, Roman Fabbricatore
| ONCOLOGY journal Verified
At the 43rd Annual Chemotherapy Foundation Symposium (CFS), hosted by Physician’s Education Resource®, LLC, oncologists gathered to discuss emerging developments in oncology. One session in particular, “Cases and Conversations: Transforming Small Cell Lung Cancer (SCLC) Treatment Through Emerging Evidence and Expert Insights (Spotlight CE Session),” gave an extensive overview of the state of SCLC across patients with both limited-stage (LS-SCLC) and extensive-stage (ES-SCLC) disease.
Open in Who Shared Issue with article?

Investigational Cell Therapy Yields Durable Complete Response in BCG-Naïve NMIBC

|
By Ram Prakash Thirugnanasambandam, Ariana Bauer, Christopher A. D’Angelo, Tim Cortese
| ONCOLOGY journal Verified
Updated interim results for TARA-002, an investigational cell therapy, as treatment for patients with carcinoma in situ (CIS) non-muscle invasive bladder cancer (NMIBC) who are Bacillus Calmette-Guérin (BCG)-naïve from the open-label phase 2 ADVANCED-2 trial (NCT05951179) have been announced in a press release from the developer, Protara Therapeutics.1 With a data cutoff of November 7, 2025, among 29 patients who were efficacy-evaluable, BCG-naïve, and received at least 1 dose of TARA-002,...
Open in Who Shared View Duplicates (2) Issue with article?
See all 9 articles